6OQ7
Structure of the GTD domain of Clostridium difficile toxin B in complex with VHH E3
Summary for 6OQ7
Entry DOI | 10.2210/pdb6oq7/pdb |
Descriptor | Toxin B, E3, URIDINE-5'-DIPHOSPHATE, ... (7 entities in total) |
Functional Keywords | toxin vhh, toxin |
Biological source | Clostridioides difficile More |
Total number of polymer chains | 2 |
Total formula weight | 78941.10 |
Authors | |
Primary citation | Chen, P.,Lam, K.H.,Liu, Z.,Mindlin, F.A.,Chen, B.,Gutierrez, C.B.,Huang, L.,Zhang, Y.,Hamza, T.,Feng, H.,Matsui, T.,Bowen, M.E.,Perry, K.,Jin, R. Structure of the full-length Clostridium difficile toxin B. Nat.Struct.Mol.Biol., 26:712-719, 2019 Cited by PubMed Abstract: Clostridium difficile is an opportunistic pathogen that establishes in the colon when the gut microbiota are disrupted by antibiotics or disease. C. difficile infection (CDI) is largely caused by two virulence factors, TcdA and TcdB. Here, we report a 3.87-Å-resolution crystal structure of TcdB holotoxin that captures a unique conformation of TcdB at endosomal pH. Complementary biophysical studies suggest that the C-terminal combined repetitive oligopeptides (CROPs) domain of TcdB is dynamic and can sample open and closed conformations that may facilitate modulation of TcdB activity in response to environmental and cellular cues during intoxication. Furthermore, we report three crystal structures of TcdB-antibody complexes that reveal how antibodies could specifically inhibit the activities of individual TcdB domains. Our studies provide novel insight into the structure and function of TcdB holotoxin and identify intrinsic vulnerabilities that could be exploited to develop new therapeutics and vaccines for the treatment of CDI. PubMed: 31308519DOI: 10.1038/s41594-019-0268-0 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.39 Å) |
Structure validation
Download full validation report